AC Immune Statistics
Total Valuation
AC Immune has a market cap or net worth of $242.10 million. The enterprise value is $153.92 million.
| Market Cap | 242.10M |
| Enterprise Value | 153.92M |
Important Dates
The next estimated earnings date is Tuesday, November 3, 2026, before market open.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AC Immune has 99.43 million shares outstanding. The number of shares has increased by 1.25% in one year.
| Current Share Class | 99.43M |
| Shares Outstanding | 99.43M |
| Shares Change (YoY) | +1.25% |
| Shares Change (QoQ) | +6.67% |
| Owned by Insiders (%) | 5.71% |
| Owned by Institutions (%) | 4.73% |
| Float | 39.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 42.95 |
| PS Ratio | 11.17 |
| Forward PS | 31.80 |
| PB Ratio | 5.56 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.12.
| Current Ratio | 0.93 |
| Quick Ratio | 0.89 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -204.20 |
Financial Efficiency
Return on equity (ROE) is -78.53% and return on invested capital (ROIC) is -45.93%.
| Return on Equity (ROE) | -78.53% |
| Return on Assets (ROA) | -16.04% |
| Return on Invested Capital (ROIC) | -45.93% |
| Return on Capital Employed (ROCE) | -87.12% |
| Weighted Average Cost of Capital (WACC) | 12.62% |
| Revenue Per Employee | $177,619 |
| Profits Per Employee | -$437,794 |
| Employee Count | 122 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.03% in the last 52 weeks. The beta is 1.55, so AC Immune's price volatility has been higher than the market average.
| Beta (5Y) | 1.55 |
| 52-Week Price Change | -16.03% |
| 50-Day Moving Average | 2.64 |
| 200-Day Moving Average | 2.78 |
| Relative Strength Index (RSI) | 42.34 |
| Average Volume (20 Days) | 216,728 |
Short Selling Information
The latest short interest is 3.52 million, so 7.59% of the outstanding shares have been sold short.
| Short Interest | 3.52M |
| Short Previous Month | 3.48M |
| Short % of Shares Out | 7.59% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 21.42 |
Income Statement
In the last 12 months, AC Immune had revenue of $21.67 million and -$53.41 million in losses. Loss per share was -$0.53.
| Revenue | 21.67M |
| Gross Profit | -35.15M |
| Operating Income | -54.08M |
| Pretax Income | -53.41M |
| Net Income | -53.41M |
| EBITDA | -52.57M |
| EBIT | -54.08M |
| Loss Per Share | -$0.53 |
Balance Sheet
The company has $93.26 million in cash and $5.08 million in debt, with a net cash position of $88.19 million or $0.89 per share.
| Cash & Cash Equivalents | 93.26M |
| Total Debt | 5.08M |
| Net Cash | 88.19M |
| Net Cash Per Share | $0.89 |
| Equity (Book Value) | 43.53M |
| Book Value Per Share | 0.44 |
| Working Capital | -8.46M |
Cash Flow
In the last 12 months, operating cash flow was -$61.23 million and capital expenditures -$720,306, giving a free cash flow of -$61.95 million.
| Operating Cash Flow | -61.23M |
| Capital Expenditures | -720,306 |
| Depreciation & Amortization | 1.48M |
| Net Borrowing | -1.16M |
| Free Cash Flow | -61.95M |
| FCF Per Share | -$0.62 |
Margins
Gross margin is -162.23%, with operating and profit margins of -249.58% and -246.48%.
| Gross Margin | -162.23% |
| Operating Margin | -249.58% |
| Pretax Margin | -246.48% |
| Profit Margin | -246.48% |
| EBITDA Margin | -242.61% |
| EBIT Margin | -249.58% |
| FCF Margin | n/a |
Dividends & Yields
AC Immune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.25% |
| Shareholder Yield | -1.25% |
| Earnings Yield | -22.06% |
| FCF Yield | -25.59% |
Analyst Forecast
The average price target for AC Immune is $8.57, which is 251.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.57 |
| Price Target Difference | 251.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 211.24% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AC Immune has an Altman Z-Score of -3.94. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.94 |
| Piotroski F-Score | n/a |